Back to Top Skip to main content

DTRA contributes to historic Ebola vaccine effort

Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz) Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz)

Recommended Content:

Immunization Healthcare | Immunizations | Global Emerging Infections Surveillance | Global Health Engagement | Global Health Engagement

FORT BELVOIR, Va. — The team of researchers and program managers at the Defense Threat Reduction Agency (DTRA) that has worked to counter the threat of the Ebola Virus Disease (EVD) welcomed the announcement of the U.S. Food and Drug Administration’s (FDA) approval of the vaccine, Ervebo ®, to the pharmaceutical company Merck & Co., Inc., December 19, 2019.

The approval of the vaccine represents the culmination of nearly two decades of efforts by a host of teams from across the public and private sectors such as DTRA and Merck, international partners in North America, Europe and Africa, and non-governmental and international organizations. The World Health Organization (WHO) describes EVD as a rare but severe hemorrhagic fever. EVD has killed thousands over the course of outbreaks, primarily in sub-Saharan Africa, since it first appeared in the 1970s.

DTRA, a Department of Defense combat support agency that identifies and combats biological threats as part of its mission to counter weapons of mass destruction (WMD), began its work on the vaccine in 2014 during an especially deadly outbreak in West Africa. The outbreak made clear the danger EVD posed to U.S. national security interests abroad, as well as to the U.S. domestic population in the event of a pandemic. To counter the threat, DTRA quickly initiated a strategy to get a vaccine approved. The combat support agency coordinated a series of investment efforts and partnerships to deliver a baseline platform for a viable vaccine candidate to mitigate the spread of the deadly disease.

“DTRA’s agile contracting, and well-placed contacts throughout government, academia, and industry allowed DTRA to form partnerships and guide development of this vaccine from the early stages of development, through crucial preclinical, and critical phase 1 clinical safety trials to the actual phase 2 clinical efficacy trial that demonstrated effectiveness of this vaccine during the outbreak,” said L. Revell Phillips Ph.D., a member of DTRA’s research and development team.

DTRA’s pioneering approach started with a contract to BioProtection Systems, a small biotech company. DTRA and BioProtection Systems partnered with Public Health Agency Canada, who began developing the vaccine in 2001, to accelerate its development. With these three teams working together, the vaccine progressed to a series of nonclinical and clinical studies conducted at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) and Walter Reed Army Institute of Research (WRAIR) defense laboratories.

As the effort evolved, DTRA leveraged its USAMRIID partner’s research capacity, resulting in international partnering agreements with the WHO. DTRA also coordinated with teams across the U.S. government as development of the vaccine progressed. The efforts of this research and development consortium produced viable data that would be transitioned to next-level partners.

“We exercised our ability to develop partnerships for a relevant need, which was critical in transitioning medical countermeasures to our advanced developers at the speed of relevancy,” said Army Maj. Jeffrey Froude, DTRA’s program manager for the EVD Vaccine.

Froude explained that DTRA bolstered its research and development investments through two key U.S. governmental partners. First, DTRA worked closely with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, for advanced trials and manufacturing activities. Second, DTRA teamed with the DoD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for the task of immunoassay development. For that development effort, JPEO-CBRND’s, office of the Joint Program Manager for CBRN Medical took the lead.

Following several years of coordinated research and development efforts by the coalition of partners, the promising vaccine candidate transitioned to next-level partners BARDA and Merck for more advanced human clinical trials and product manufacturing of the EVD vaccine.

“This vaccine’s rapid progress is a testament to the power of partnerships among government agencies and with the private sector,” said BARDA director Rick Bright.

Next-level partner BARDA and Merck, served as the transition point to conduct more advanced human clinical trials and product manufacturing on the Ebola vaccine with the Joint Program Executive office (JPEO) providing a testing capability that allowed Merck to test human and non-human primate samples. The Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical (JPM-CBRN), Army Col. Ryan Eckmeier, stated that this “interagency partnership from the beginning was critical to advancing this vaccine product.”

Merck’s expertise with licensing and manufacturing was instrumental in advancing the vaccine. The pharmaceutical giant partnered with the WHO, United Nations International Children's Emergency Fund, and Gavi Vaccine Alliance, among others, to strategize on how to best implement future public health preparedness and response efforts against EVD.

“We share in this achievement, and thank you all personally for your amazing support over the last five years,” said Beth-Ann G. Coller, executive director of Merck’s vaccine team in a note to the DTRA team. “This has truly been a journey and one that we are proud to have shared with our colleagues in DoD. Without the early and continued support of DTRA we would not be here today.”

DTRA continues to leverage its successful partnerships as the agency works to develop future countermeasures. DTRA and BARDA have active partnering agreements to develop vaccine and therapeutic medical countermeasures to address a diverse range of viral and bacterial infectious disease threats. Efforts will use a similar model to the one that supported development and approval of the EVD vaccine.

“As DTRA moves forward to new challenges, we will leverage continued utilization of the Ebola vaccine model, using a diverse range of ways that we can work with our academic, international, interagency and industrial partners through grants, contracts and other transaction authorities,” said Froude. “We have a proven paradigm on how to efficiently advance medical countermeasures working with our U.S. government partners in these endeavors.”

Disclaimer: Re-published content may be edited for length and clarity. Read original post.

You also may be interested in...

Leaders take world view to enhance health readiness

Article
12/19/2018
Army Maj. Elizabeth Polfer (left), an orthopedic surgeon at William Beaumont Army Medical Center in Texas, performs hand surgery with her Honduran counterpart in Tegucigalpa, Honduras, during a Regional Health Command-Central Global Health Engagement Medical Readiness Training Exercise. (U.S. Army photo by Maria Pinel)

Global engagements include missions in South, Central America

Recommended Content:

Global Health Engagement | Global Health Engagement

Vaccination is the best defense against the flu

Article
12/10/2018
Vaccination is the primary method for preventing influenza and its complications and getting an annual influenza vaccine is the best way to protect yourself and your family from the flu. (U.S. Army photo by Staff Sgt. Erica Knight)

Vaccination is needed every year because the Influenza viruses change

Recommended Content:

Health Readiness | Immunization Healthcare | Immunizations

Updated Framework for Development of Evidence-Based Recommendations by the Advisory Committee on Immunization Practices

Report
11/16/2018

In 2010, the Advisory Committee on Immunization Practices (ACIP) implemented the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for developing evidence-based recommendations. Since its February 2018 meeting, ACIP has incorporated the use of Evidence to Decision or Evidence to Recommendation (EtR) frameworks into GRADE methodology.

Recommended Content:

Immunization Healthcare | Vaccine Recommendations

Global Routine Vaccination Coverage — 2017

Report
11/16/2018

Global coverage with vaccines to prevent diphtheria, tetanus, pertussis, polio, and measles has remained at 84%–85% since 2010. Prioritizing countries with the highest number of unvaccinated children to implement context-specific strategies has the potential to increase immunization coverage globally.

Recommended Content:

Immunization Healthcare | Measles-Mumps-Rubella | Polio | Tetanus-Diphtheria-Pertussis

WRAIR begins Phase 1 clinical trial of Marburg vaccine

Article
10/19/2018
The WRAIR study evaluates the VRC-MARADC087-00-VP vaccine, developed by the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. (U.S. Army file photo)

WRAIR recently administered the first vaccine in a Phase 1 clinical trial to evaluate the safety and immunogenicity of a Marburg vaccine

Recommended Content:

Immunization Healthcare | Immunizations

Navy entomologists team up to build disease detection capacity in Honduras

Article
10/18/2018
Navy LCDR Kimberly Edgel (right) and Carmen Lucas examine a positive malaria blood smear at U.S. Naval Medical Research Unit, or NAMRU, 6 in Callao, Peru. (U.S. Navy photo)

Leishmaniasis, malaria, dengue and Chagas disease are known to be present in Honduras

Recommended Content:

Global Health Engagement | Global Health Engagement

Bringing Comfort 2018

Video
10/17/2018
The USNS Comfort is a state-of-the-art hospital ship, and it’s scheduled to deploy to Central and South America for Continuing Promise 2018.

The USNS Comfort is a state-of-the-art hospital ship, and it’s scheduled to deploy to Central and South America for Continuing Promise 2018.

Recommended Content:

Global Health Engagement | Global Health Engagement

Vaccination Coverage Among Children Aged 19–35 Months — United States, 2017

Report
10/12/2018

The Advisory Committee on Immunization Practices recommends routine vaccination by age 24 months against 14 potentially serious illnesses. In 2017, coverage with most recommended vaccines among children aged 19–35 months remained stable and high but was lower in more rural areas and among uninsured or Medicaid-insured children.

Recommended Content:

Immunization Healthcare | Vaccine-Preventable Diseases | Vaccine Schedules

Vaccination Coverage for Selected Vaccines and Exemption Rates Among Children in Kindergarten — United States, 2017–18 School Year

Report
10/12/2018

Immunization programs conduct annual kindergarten vaccination assessments to monitor school-entry vaccination coverage for all state-required vaccines. Median vaccination coverage was 94.3% for 2 doses of measles, mumps, and rubella vaccine; 95.1% for the state-required number of doses of diphtheria and tetanus toxoids and acellular pertussis vaccine; and 93.8% for 2 doses of varicella vaccine.

Recommended Content:

Immunization Healthcare | Vaccine-Preventable Diseases | Vaccine Schedules

Sailors, Afghan medical professionals team up to improve medical care

Article
10/10/2018
Navy Lt. Cdr. Travis J. Fitzpatrick, senior nurse for Kandahar Airfield NATO Role III Multinational Medical Unit, demonstrates a technique on how to clear the airway of a patient to Afghan medical staff members during a medical advisory visit at Kandahar Regional Military Hospital, Camp Hero in Kandahar, Afghanistan. Staff members from the Role III conduct routine visits to KRMH to train and advise Afghan medical staff. (U.S. Army photo by Staff Sgt. Neysa Canfield)

The Kandahar Regional Military Hospital is run by Afghan military and civilian medical professionals

Recommended Content:

Global Health Engagement | Building Partner Capacity and Interoperability | Partners | Global Health Security Agenda | Global Health Engagement

USNS Comfort to deploy to Central and South America

Article
10/9/2018
The U.S. Navy hospital ship USNS Comfort is scheduled to depart Naval Station Norfolk, Virginia, en route to South America and Central America where it will conduct an 11-week medical assistance mission working closely with host-nation health and government partners in Ecuador, Peru, Colombia, and Honduras. This mission marks the sixth time the hospital ship will provide medical assistance in the region and reflects the United States’ enduring promise of friendship, partnership, and solidarity with the Americas. (U.S. Navy file photo)

The ship’s crew will include more than 200 U.S. and partner nation military doctors, nurses and technicians

Recommended Content:

Global Health Engagement | Partners | Global Health Security Agenda | Global Health Engagement

Say ‘Shoo’ to the flu with TRICARE

Article
9/26/2018
Amanda LaFountain, a licensed practical nurse, administers the flu shot to a Soldier. (U.S. Army photo by Staff Sgt. Marshall Metzger)

Flu viruses are serious, contagious viruses that can lead to hospitalization or even death

Recommended Content:

Health Readiness | Immunization Healthcare | Public Health

2019 to 2021 GEIS Strategy

Report
6/15/2018

This Strategy describes how GEIS will support infectious disease surveillance and outbreak response to enhance FHP decision making in the future operating environment. GEIS will achieve this end state through direct support to the six Geographic Combatant Commands (GCC) and the global DoD laboratory network that operates in all of their areas of operation to provide early detection, prevention and response to infectious disease threats of military relevance.

Recommended Content:

Global Emerging Infections Surveillance

2018 Medical Support Operations Conference

Photo
4/11/2018
Acting Assistant Secretary of Defense for Health Affairs Tom McCaffery spoke at the 2018 Medical Support Operations Conference in London, delivering remarks on the defense sector's role in advancing the Global Health Security Agenda. A partnership of more than 60 nations, the Global Health Security Agenda, or GHSA, brings together the unique roles of governments, industry, NGOs, academia, and international institutions to combat infectious disease threats. “We are up against a perilous rise in infectious disease outbreaks threatening the health and safety of our citizens, as well as threatening geopolitical stability,” stated McCaffery, emphasizing that global health security is an essential part of our national security. “The bottom line is that defense and security sectors have a real opportunity to use the GHSA framework to increase collaboration and converge our unique assets across all sectors to detect and defeat disease at the earliest possible moment," McCaffery said.

Acting Assistant Secretary of Defense for Health Affairs Tom McCaffery spoke at the 2018 Medical Support Operations Conference in London, delivering remarks on the defense sector's role in advancing the Global Health Security Agenda. A partnership of more than 60 nations, the Global Health Security Agenda, or GHSA, brings together the unique roles of governments, industry, NGOs, academia, and international institutions to combat infectious disease threats. “We are up against a perilous rise in infectious disease outbreaks threatening the health and safety of our citizens, as well as threatening geopolitical stability,” stated McCaffery, emphasizing that global health security is an essential part of our national security. “The bottom line is that defense and security sectors have a real opportunity to use the GHSA framework to increase collaboration and converge our unique assets across all sectors to detect and defeat disease at the earliest possible moment," McCaffery said.

Recommended Content:

Global Health Engagement

2018 Visit to U.S. Africa Command's Command Surgeon

Photo
4/11/2018
Acting Assistant Secretary of Defense for Health Affairs Tom McCaffery visits U.S. Africa Command's Command Surgeon and team to discuss the strategic context of global health in advancing shared security objectives with partner nations across the region.  The Department of Defense recognizes that Global Health Engagement activities play a key role to advance U.S. troop operational readiness, build interoperability, and enhance Security Cooperation.

Acting Assistant Secretary of Defense for Health Affairs Tom McCaffery visits U.S. Africa Command's Command Surgeon and team to discuss the strategic context of global health in advancing shared security objectives with partner nations across the region. The Department of Defense recognizes that Global Health Engagement activities play a key role to advance U.S. troop operational readiness, build interoperability, and enhance Security Cooperation.

Recommended Content:

Global Health Engagement | Global Health Engagement
<< < ... 6 7 8 9 10  ... > >> 
Showing results 76 - 90 Page 6 of 12

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.